Literature DB >> 12023039

Methadone induces CCR5 and promotes AIDS virus infection.

Shunji Suzuki1, Maria P Carlos, Linda F Chuang, José V Torres, Roy H Doi, Ronald Y Chuang.   

Abstract

Methadone, a regimen for the treatment of opioid dependency, was found to induce the expression of CCR5, a co-receptor for human immunodeficiency virus (HIV)/simian form of HIV (SIV) entry, on human CEM x174 lymphocytes. Both CCR5 mRNA and protein were elevated in methadone-treated cells. A concomitant increase of mu opioid receptors was also observed. Upon methadone exposure, SIVmac239-infected CEM x174 cells released greater amounts of virus particles as revealed by both the number of syncytia formation and reverse transcriptase activities. Similar methadone effect was not observed on CEM x174 cells infected with other simian retroviruses that do not depend on CCR5 for cellular entry. These studies raise concerns considering methadone as an innocuous morphine substitute.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12023039     DOI: 10.1016/s0014-5793(02)02746-1

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  21 in total

Review 1.  Opioids and HIV/HCV infection.

Authors:  Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-14       Impact factor: 4.147

2.  Improved parameters of metabolic glycaemic and immune function and arterial stiffness with naltrexone implant therapy.

Authors:  Albert Stuart Reece
Journal:  BMJ Case Rep       Date:  2009-04-14

Review 3.  Drugs of abuse and HIV infection/replication: implications for mother-fetus transmission.

Authors:  Xu Wang; Wen-Zhe Ho
Journal:  Life Sci       Date:  2010-11-04       Impact factor: 5.037

Review 4.  Epigenetics of µ-opioid receptors: intersection with HIV-1 infection of the central nervous system.

Authors:  Patrick M Regan; Rajnish S Dave; Prasun K Datta; Kamel Khalili
Journal:  J Cell Physiol       Date:  2012-07       Impact factor: 6.384

5.  CCR5 mediates HIV-1 Tat-induced neuroinflammation and influences morphine tolerance, dependence, and reward.

Authors:  Maciej Gonek; Virginia D McLane; David L Stevens; Kumiko Lippold; Hamid I Akbarali; Pamela E Knapp; William L Dewey; Kurt F Hauser; Jason J Paris
Journal:  Brain Behav Immun       Date:  2017-11-13       Impact factor: 7.217

6.  Morphine enhances HIV infection of human blood mononuclear phagocytes through modulation of beta-chemokines and CCR5 receptor.

Authors:  Chang-Jiang Guo; Yuan Li; Sha Tian; Xu Wang; Steven D Douglas; Wen-Zhe Ho
Journal:  J Investig Med       Date:  2002-11       Impact factor: 2.895

7.  Alterations of expression of inflammation/immune-related genes in the dorsal and ventral striatum of adult C57BL/6J mice following chronic oxycodone self-administration: a RNA sequencing study.

Authors:  Yong Zhang; Yupu Liang; Orna Levran; Matthew Randesi; Vadim Yuferov; Connie Zhao; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2017-06-26       Impact factor: 4.530

8.  Morphine enhances HIV infection of neonatal macrophages.

Authors:  Yuan Li; Jeffrey D Merrill; Kathy Mooney; Li Song; Xu Wang; Chang-Jiang Guo; Rashmin C Savani; David S Metzger; Steven D Douglas; Wen-Zhe Ho
Journal:  Pediatr Res       Date:  2003-05-07       Impact factor: 3.756

9.  A novel bivalent HIV-1 entry inhibitor reveals fundamental differences in CCR5-μ-opioid receptor interactions between human astroglia and microglia.

Authors:  Nazira El-Hage; Seth M Dever; Elizabeth M Podhaizer; Christopher K Arnatt; Yan Zhang; Kurt F Hauser
Journal:  AIDS       Date:  2013-09-10       Impact factor: 4.177

10.  Preferential vulnerability of astroglia and glial precursors to combined opioid and HIV-1 Tat exposure in vitro.

Authors:  Valeriya K Khurdayan; Shreya Buch; Nazira El-Hage; Sarah E Lutz; Susan M Goebel; Indrapal N Singh; Pamela E Knapp; Jadwiga Turchan-Cholewo; Avindra Nath; Kurt F Hauser
Journal:  Eur J Neurosci       Date:  2004-06       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.